首页> 美国卫生研究院文献>Critical Care >Serum activin A and B levels predict outcome in patients with acute respiratory failure: a prospective cohort study
【2h】

Serum activin A and B levels predict outcome in patients with acute respiratory failure: a prospective cohort study

机译:血清激活素A和B水平可预测急性呼吸衰竭患者的预后:一项前瞻性队列研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Introduction30 day mortality in patients with Acute Respiratory Failure (ARF) is approximately 30%, defined as patients requiring ventilator support for more than 6 hours. Novel biomarkers are needed to predict patient outcomes and to guide potential future therapies. The activins A and B, members of the Transforming Growth Factor β family of proteins, and their binding protein, follistatin, have recently been shown to be important regulators of inflammation and fibrosis but no substantial data are available concerning their roles in ARF.Our objectives were to evaluate whether the serum levels of activin A, B and follistatin are elevated in 518 patients with ARF from the FINNALI study compared the concentrations in 138 normal subjects that form a reference range.
机译:简介急性呼吸衰竭(ARF)患者的30天死亡率约为30%,定义为需要呼吸机支持超过6小时的患者。需要新型的生物标志物来预测患者的预后并指导未来的潜在疗法。最近发现,转化生长因子β蛋白家族成员激活素A和B及其结合蛋白卵泡抑素是炎症和纤维化的重要调节剂,但尚无关于其在ARF中作用的大量数据。评估来自FINNALI研究的518名ARF患者的血清活化素A,B和卵泡抑素水平是否升高,并比较了138个正常受试者的血脂水平(形成参考范围)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号